Medication Updates

New Biosimilar for Macular Degeneration and Retinopathy | AFLIBERCEPT (Eylea) Medication Update New Biosimilar for Macular Degeneration and Retinopathy Although we hear the word biosimilar commonly now in medication management, the biosimilars coming to market stretch well beyond the new biosimilar for Humira. Disease treatment moved from the use of chemical compounds to biologics years…

New Oral Option for patients with Anemia due to CKD on Dialysis | Jesduvroq Medication Update New Oral Option for patient with Anemia due to CKD on Dialysis On February 1, 2023, the FDA approved GlaxoSmithKline’s oral therapy, Jesduvroq (daprodustat), for the treatment of anemia due to chronic kidney disease (CKD) on dialysis.1 Notably, sources…

New SGLT2 inhibitor for Diabetes Type 2 | Brenzavvy Medication Update New SGLT2 inhibitor for Diabetes Type 2 On January 23, 2023, the FDA approved Brenzavvy (bexagliflozin) made by TheracosBio for the treatment of adults with type 2 diabetes.1 Brenzavvy is a SGLT2 inhibitor that lowers blood sugar by causing the removal of sugar from the…

First biosimilar for Humira® now available | Amjevita™ Medication Update First biosimilar for Humira® now available Availability of Amjevita™, the first biosimilar for Humira®, rocked the headlines on January 31, 2023. Amjevita™ (adalimumab-atto), a citrate-free biosimilar to Humira® (adalimumab), is now available in the U.S.1Similar to the Humira, Amjevita carries all the same indications for:2Rheumatoid…